The MalVax Endpoints & Trial Design Working Group ("WG1: Endpoints") will help to harmonise approaches and maximise comparability across future Phase 1–3 clinical trials performed by independent groups; consider evaluation methods that, where possible, assess the full impact/value of next-generation malaria vaccines R&D; and facilitate future regulatory approval and policy guidance. The Working Group is expected to include two workstreams: one on Individual Protection and another one on Community Protection.

The MalVax Assays Working Group ("WG2: Assays") will produce outputs that help harmonise assay approaches to accelerate vaccine development and candidate down-selection, improve comparability across future Phase 1–3 clinical trials, strengthen understanding of immunological correlates of protection, inform full impact/value assessment/proposition of next-gen vaccines, and may facilitate future regulatory approvals and policy decisions. The WG will build upon, with and across the work of the community towards defined outputs that are achievable and that bring value to pre-clinical and clinical research groups.

The MalVax Modelling Working Group ("WG3: Modelling") will establish a collaborative modelling forum that connects modelling groups and the broader malaria vaccine R&D community. The WG will synthesise the current state of modelling, identify priority questions with partners, and support the modelling community to collaborate with leading vaccine candidates in Phase 2 and 3 development. Through an open, community-oriented forum, the WG will help translate modelling insights into practical guidance that serves developers, trialists, regulators, and policy-makers at country and international levels.